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Summary
The coordination of signalling pathways within the cell is vital for normal human development and post-natal tissue homeostasis. Gene
expression and function is therefore tightly controlled at a number of levels. We investigated the role that post-translational
modifications play during human hepatocyte differentiation. In particular, we examined the role of the small ubiquitin-like modifier
(SUMO) proteins in this process. We used a human embryonic stem cell (hESC)-based model of hepatocyte differentiation to follow
changes in protein SUMOylation. Moreover, to confirm the results derived from our cell-based system, we performed in vitro
conjugation assays to characterise SUMO modification of a key liver-enriched transcription factor, HNF4a. Our analyses indicate that
SUMOylation plays an important role during hepatocellular differentiation and this is mediated, in part, through regulation of the
stability of HNF4a in a ubiquitin-dependent manner. Our study provides a better understanding of SUMOylation during human
hepatocyte differentiation and maturation. Moreover, we believe the results will stimulate interest in the differentiation and phenotypic
regulation of other somatic cell types.
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Introduction
The coordination of signalling pathways within the cell is vital for
human embryonic development and post-natal tissue homeostasis
(Vaillancourt and Lafond, 2009). This requires the regulation of
gene expression at multiple levels (Chen and Rajewsky, 2007),
including protein post-translational modification (PTM). Protein
PTMs involve the addition of a chemical group, following protein
translation, regulating protein behaviour in the cell. PTMs are
usually reversible (Hannoun et al., 2010a) and our studies centred
on the small ubiquitin-like modifier (SUMO).
SUMOylation is a widely studied modification that elicits a
wide range of effects within the cell (Johnson, 2004). SUMO
proteins are highly conserved in a large number of species and
have been shown to be important in many eukaryotic cell
processes (Hannoun et al., 2010a). Three homologues exist in
mammals, SUMO1, SUMO2 and SUMO3. SUMO2 and SUMO3
share 95% homology with each other, but only share 50%
homology with SUMO1 (Johnson, 2004) resulting in different
biological activities. SUMO2 and SUMO3 possess the ability to
form polySUMO chains via the lysine residue at the N-terminus
consensus motif (Mu¨ller et al., 2001). SUMO1 lacks this
consensus site and is therefore unable to form polySUMO
chains (Kroetz, 2005) and often acts as a polySUMO chain
terminator (Ulrich, 2009).
In order to study SUMOylation in a homologous system, we
used an efficient and high-fidelity human embryonic stem cell
(hESC) hepatocyte differentiation model (Hay et al., 2008).
hESCs possess two important qualities: self-renewal and
pluripotency (Thomson et al., 1998; Reubinoff et al., 2000).
These properties allow large numbers of undifferentiated cells
to be scaled up, prior to differentiation, generating a source
of primary somatic cell derivatives from stable and known
genotype. SUMO modification has already been shown to play an
important role in both stem cell self-renewal and in somatic cells
(Hannoun et al., 2010a). However, SUMOylation has not yet
been studied in a stem-cell-derived developmental system. Our
studies centred on the role of SUMOylation in the derivation of
human hepatocytes from hESCs.
Given the importance of SUMOylation in cell biology,
improving our understanding of this process is vital. Such
studies will undoubtedly lead to an improved understanding of
human development and cell physiology. Additionally, the
development of high-fidelity cell-based resources from
renewable sources, such as stem cells, has a significant role to
play in many aspects of modern medicine (Hannoun et al., 2010b).
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SUMOylation during human embryonic stem cell self
renewal and hepatocyte differentiation
In order to gain insight into the roles that post translational
modifications play during hESC self-renewal and differentiation,
protein SUMOylation was investigated. Human ESCs were
differentiated into hepatocytes using a robust procedure (Hay
et al., 2008) and cell extracts were harvested at various time
points throughout the differentiation process. Cell lysates were
separated by SDS-PAGE and probed for SUMO1, SUMO2,
SENP7, hepatocyte nuclear factor 4a (HNF4a) and albumin,
with b-actin used as a loading control (Fig. 1). The results
demonstrated that high levels of SUMO1-, but not SUMO2-
modified proteins were present in hESC populations undergoing
self-renewal (Fig. 1A,B). The number of SUMO1-modified
proteins decreased substantially as the cells differentiated
towards the primitive streak (day 1) (Hay et al., 2008; Medine
et al., 2011). By contrast, SUMO2 modification was increased at
this time point. In both cases, SUMO1- and SUMO2-modified
proteins were detected during definitive endoderm specification
(days 2 and 3), whereas high levels of SUMO1-, but not SUMO2-
modified proteins, were detected during hepatic specification
(day 5). During hepatocyte maturation we observed a decrease in
the levels of SUMO1- and SUMO2-modified proteins (days 7–
17) (Fig. 1A,B). This observation was reinforced by increased
expression of the SUMO-deconjugating enzyme SENP7 at the
onset of hepatic maturation (Fig. 1C).
At the point of hepatic commitment (day 7), and in line with
human liver development, we observed production of HNF4a. As
cellular differentiation progressed, hESC-derived hepatocytes
matured and expressed increasing levels of albumin. This was
paralleled by decreasing levels of HNF4a (Fig. 1C) and merited
further investigation. The reduction of HNF4a protein stability
was also accompanied by a decrease in HNF4a message and
was observed for all six isoforms of HNF4a during hepatic
differentiation (supplementary material Fig. S1). As HNF4a was
expressed ubiquitously in hESC-derived hepatocytes (92.464.5%)
and in most albumin positive cells (83.969.8%), the reduction in
HNF4a expression was most likely exhibited by all cells in our
populations.
Identification and mapping of HNF4a SUMO modification
sites in vitro
To assess whether SUMO modification was likely to play a role in
HNF4a biology we examined the HNF4a amino acid sequence for
potential SUMO modification consensus sites. We identified two
potential SUMO modification sites. One site was present in the
amino terminus and one in the carboxy terminus. In order to
determine whether these sites were used during HNF4a
SUMOylation we performed deletion analysis. N- and C-terminus
deletion mutants of HNF4a were cloned, expressed and purified
(Fig. 2A). Subsequently, we assessed the ability of these proteins to
undergo SUMOylation using an established in vitro SUMOylation
assay (Tatham et al., 2008; Shen et al., 2009). The data presented in
Fig. 2B confirmed that HNF4a was modified by SUMO (Fig. 2Bi)
and that the SUMOylation site used in this process was not found
on the N-terminus (Fig. 2Bii) but on the C-terminus (Fig. 2Biii).
These experiments were controlled by the inclusion of a SUMO
specific protease control (denoted +) which cleaved SUMO
modified HNF4a (Fig. 2B). In order to confirm the absolute
requirement for the C-terminal consensus site in this process, we
cloned truncated versions of HNF4a, which contained the wild-
type or point-mutated SUMO consensus motif Y-K-x-D/E at
residues 364–367. In the point mutant, the lysine residue at position
365 was mutated to an arginine residue and the aspartic acid residue
367 was mutated to an alanine residue using site-directed
mutagenesis. The protein was then expressed, purified and used
in our in vitro SUMO assay as before. We did not detect SUMO
modification of the point mutated HNF4a indicating that HNF4a
SUMOylation proceeds through the SUMO consensus site at the
C-terminus in vitro.
SUMO modification of HNF4a during hepatocellular
differentiation
In order to establish whether HNF4a was SUMO modified during
hepatocyte differentiation, we collected and analysed cell lysates
by immunoprecipitation. HNF4a was specifically purified from
cell extracts using HNF4a antibody covalently to crosslinked
Protein-G–Sepharose beads and compared to an IgG isotype
crosslinked control throughout (Fig. 3). Immunoprecipitated
complexes were separated by SDS-PAGE, Western blotted and
probed for SUMO1 and SUMO2 using specific antisera. HNF4a
Fig. 1. SUMOylation during human embryonic stem cell self-renewal
and hepatocyte differentiation. (A,B) Cell extracts were collected at various
time points throughout the differentiation procedure (days 0–17) and
separated by SDS-PAGE. Western blots were probed for SUMO1, SUMO2,
SENP7, hepatocyte nuclear factor 4 a (HNF4a), albumin (ALB) and b-actin.
A decrease in SUMO-modified proteins is observed as the cells commit to
hepatic endoderm. (C) During stem cell differentiation to hepatocytes we
observed an increase in levels of the SUMO-deconjugating enzyme SENP7
and the serum protein albumin. We detected HNF4a expression from day 7,
which decreased at days 15 and 17. (D) Day 17 hepatocytes were fixed and
stained for DNA (A), HNF4a (B), albumin (C) and overlaid (D). The
percentage of positive cells (shown top right on each panel) was calculated
from five random fields of view and are quoted 6 1 s.d.


















was modified with SUMO2, but not SUMO1 during hESC
hepatocellular differentiation. Interestingly, as the levels of
HNF4a decreased during the differentiation process (Fig. 1B),
there was an increase in the level of SUMO2-modified HNF4a,
indicating that SUMO2 may regulate HNF4a stability (Fig. 3).
PolySUMOylation marks HNF4a for RNF4-mediated
ubiquitination in vitro
Recent developments in the field have shown that
polySUMOylation can serve as a template for RNF4-mediated
ubiquitination and protein degradation (Tatham et al., 2008).
RNF4 is an ubiquitin E3 ligase with specific SUMO interaction
motifs (SIM) that facilitate its interaction and ubiquitin transfer to
polySUMOylated proteins (Sun et al., 2007). In order to study
this in vitro, HNF4a was used in its native state or conjugated
with SUMO1 or SUMO2 (Fig. 4A). Subsequently, HNF4a was
incubated in the presence or absence of RNF4, and ubiquitin.
Three hours post incubation HNF4a was immunoprecipitated,
Fig. 2. Mapping SUMO modification of HNF4a in vitro. (A) HNF4a WT and the various deletion mutants were generated in order to identify the region of
SUMO modification in HNF4a. HNF4a contains a functional domain structure, which includes the activation domains (AD-1 and AD-2), the DNA binding
domain (DNA BD), the ligand binding domain (LBD) and the repression domain (RD). (B) The in vitro SUMO assay contains the specified form of HNF4a and
the SUMO conjugation machinery (E1-SAE1/2 and E2-Ubc9). The use of the deletion constructs and the point mutant (Lys365 to Arg365 and Asp367 to Ala367)
demonstrates that the C-terminus in HNF4a is absolutely required for SUMOylation in vitro. The control reaction contained the SUMO-deconjugating enzyme
SENP1. SUMO conjugation resulted in a ,10 kDa shift in protein mass, whereas SUMO deconjugation was measured by the disappearance of the band in the
presence of SENP1.
Fig. 3. SUMO modification of HNF4a during hepatocellular
differentiation. hESCs were differentiated to hepatocytes and samples were
harvested at the time points indicated. HNF4a was pulled down using HNF4a
antibody covalently crosslinked to Protein-G–Sepharose. An IgG isotype was
used as a control throughout. Following incubation and extensive washing,
the beads were eluted, separated by SDS-PAGE, western blotted and probed
for SUMO1 and SUMO2. We did not detect SUMO1 modification of HNF4a
during the differentiation processes. By contrast, we observed an increase in
HNF4a SUMO2 modification as differentiation progressed. Our negative
control IgG demonstrated that our assay was operating specifically throughout.
Fig. 4. PolySUMOylation of HNF4a enhances RNF4-mediated
ubiquitination in vitro. (A) In order to study HNF4a ubiquitin modification in
vitro we employed an in vitro ubiquitination assay. WT HNF4a was mono- and
polySUMOylated using SUMO1 and SUMO2 but absent from the control lane.
(B) SUMOylated HNF4a protein was incubated with ubiquitination machinery
(E1 and E2) in the presence and absence of RNF4 (E3). Following assay
completion, HNF4a was immunoprecipitated and ubiquitin conjugation
analysed using western blotting. Ubiquitination only occurred in the presence of
RNF4 and was increased when HNF4a was polySUMOylated.
(C) Densitometry analysis was performed using ImageJ software. The level of
ubiquitination was increased more than sixfold over the control when HNF4a
was polySUMOylated and twofold when HNF4a was monoSUMOylated.


















separated by SDS-PAGE, probed for ubiquitin and analysed by
densitometry (Fig. 4B). RNF4-mediated HNF4a ubiquitination
was more than sixfold greater for polySUMOylated (SUMO2) and
twofold greater for monoSUMOylated (SUMO1) over unmodified
HNF4a controls (Fig. 4C).
HNF4a stability is regulated by ubiquitination during
hepatocellular maturation
To further investigate the effect of polySUMOylation and
ubiquitination on HNF4a biology, we followed the expression
of RNF4 during hESC differentiation. We observed an
upregulation of RNF4 from days 5–17 (Fig. 5A) indicating that
RNF4 was expressed in our model at the time that HNF4a was
degraded. To test the hypothesis that protein ubiquitination was
responsible for regulating HNF4a stability, we incubated day 17
hESC-derived hepatocytes in the presence of proteasome 26S
inhibitor (P26S), MG132 (Fiedler et al., 1998). Cell extracts were
harvested from two independent differentiation experiments and
analysed for HNF4a stability using western blotting and actin-
controlled densitometry (Fig. 5B,C). In the presence of MG132,
HNF4a levels were increased about fourfold, demonstrating that
ubiquitin-mediated proteolysis is an important process that
regulates the stability of HNF4a in the cell (Fig. 5B,C).
Moreover, we detected a doublet at ,75 kDa, indicating the
likely preservation of SUMO2 and ubiquitin-modified HNF4a in
the absence of P26S activity.
Loss of HNF4a results in reduced hepatocellular function
and increased oxidative stress
In order to study the effect of HNF4a proteolysis on hepatocyte
biology, we studied liver exocrine and endocrine function. We
assayed for drug bio-transformation (Cyp3A) function and serum
protein production (TTR) from days 15 to 25 during cellular
differentiation. Cyp3A function was detected at day 15 and peaked
at day 17 and then decreased until day 25 (Fig. 6A). A similar
pattern was observed for TTR with peak function detected at day 15
and decreasing thereafter (Fig. 6B). These results demonstrate that
a drop-off in Cyp3A and TTR function was in line with the loss of
HNF4a in our system. In addition to the decrease of hepatocellular
function, we also detected an increase in cellular oxidative stress as
cells lost HNF4a expression and de-differentiated in culture. This
was in line with previous studies (Marcil et al., 2010) (Fig. 6C).
Discussion
In order to coordinate human development and maintain cell
phenotype in the neonate, it is necessary to tightly regulate gene
Fig. 5. HNF4a is a target for ubiquitin-mediated degradation.
(A) Because RNF4 plays an important role in modulating HNF4a stability in
vitro, we monitored its expression during human embryonic stem cell
differentiation. RNF4 expression was observed and increased during hepatic
differentiation and maturation. (B,C) To assess whether ubiquitin-mediated
proteolysis played a central role in the stability of HNF4a, we inhibited the
26S proteasome using MG132. hESC-derived hepatocytes were incubated
with or without MG132 for 4 hours and cell extracts were collected,
separated, western blotted and probed for HNF4a. HNF4a levels increased
,fourfold in the presence of MG132, as determined by actin-controlled
densitometry.
Fig. 6. Loss of HNF4a leads to decreased hepatocellular function and
oxidative state. (A) Cyp3A metabolic activity of hESC-derived hepatocytes
was measured on days 15–25 using CYP3A pGlo substrate. 5 hours post
treatment, CYP3A activity was measured on a luminometer. Units of activity are
expressed as relative light units (RLU)/mg protein/ml (n56). Error bars
represent 1 s.d. (B) hESC-derived hepatocytes (days 15–25) were cultured in
six-well plates with 1 ml L-15 for 24 hours before culture supernatants were
collected and TTR secretion was measured by ELISA. Error bars represent 1 s.d.
(C) The redox state of hESC-derived hepatocytes was measured between days
17–25. hESC-derived hepatocytes were incubated with L-15 supplemented with
GSH/GSSG pGlo substrate and activity was measured on a luminometer.


















expression, translation and protein biology. Our studies focussed
on protein post-translational modifications. Using a bona fide
human model, we demonstrate that protein modification by
SUMO is important during hESC self-renewal and hepatic
differentiation (Fig. 1). During differentiation, we observed the
differential expression and stability of a key hepatocyte
transcription factor, HNF4a (Fig. 1, supplementary material
Fig. S1). We reasoned that SUMO modification may be
regulating HNF4a stability and function. We identified two
potential SUMOylation sites; one located in the N-terminus and
one at the C-terminus of the protein. Through deletion and point
mutation analysis we determined that the critical region for
HNF4a modification was at the consensus site found in the C-
terminus (Fig. 2). While HNF4a SUMOylation took place in
vitro, immune precipitation experiments confirmed that HNF4a
was SUMO modified during cellular differentiation and resulted
in decreased HNF4a stability (Fig. 3). This process was regulated
by ubiquitin-mediated proteolysis (Figs 4, 5) and preceded
hepatocyte de-differentiation (Fig. 6).
HNF4a is a member of the nuclear receptor family (NR) of
transcription factors. HNF4a possesses a modular structure
containing two activation domains (AD-1 and AD-2), a DNA
binding domain, a ligand binding (LBD), a dimerization domain
and repression domain (Fig. 2) (Bogan et al., 2000). The AD-2
transactivation domain (Dhe-Paganon et al., 2002) was of particular
interest in our studies (residues 360–368) because this contained the
SUMO consensus motif. The AD-2 domain lies adjacent to another
important domain of HNF4a, the ligand binding domain (LBD).
The LBD plays a pivotal role in transcriptional activity and has two
distinct conformations, open and closed (Bogan et al., 2000). The
difference between these forms is in the position of helix a12 (the
AD-2 domain). In the open conformation, a12 is extended co-
linearly with helices a10 and a11, rendering the ligand-binding
pocket accessible. The open structure does not allow the binding of
co-activator molecules, therefore it is considered to be the inactive
form. In the closed conformation, the a12 helix folds back onto the
LBD, sealing the ligand-binding pocket (Bogan et al., 2000). In this
form, HNF4a can interact with co-activators, and is considered to
be in the active state (Duda et al., 2004). Therefore, it is conceivable
that SUMOylation of HNF4a’s AD2 may directly affect the
conformation of LBD and increase HNF4a transcriptional activity
through co-factor binding. Consistent with this, we demonstrate
increasing albumin production as HNF4a is increasingly modified
by SUMO-2 (Figs 1,3). In addition to the LBD, the RD in the C-
terminus also plays a role in HNF4a transcriptional activity and is
sufficient by itself to repress the activity of the AD-2 domain
(Iyemere et al., 1998). Therefore SUMOylation at AD-2 may also
play an important role in displacing the RD and enhancing HNF4a
transcriptional activity.
In conclusion, our investigation has provided evidence that
SUMOylation of HNF4a regulates protein stability and potentially
transcriptional activity. Dysregulation of this process results in the
loss of HNF4a and hepatic function, demonstrating its importance
in maintaining the hepatocellular phenotype. We believe our
studies are novel and will stimulate interest in the differentiation
and phenotypic regulation of other cell types.
Materials and Methods
hESC culture
H1 hESCs were cultured as previously described (Fletcher et al., 2008; Hay et al.,
2011). H1 hESCs were differentiated into HE as described (Hay et al., 2008) and
characterised using standard criteria (Hannoun et al., 2010c).
hESC-derived hepatocyte characterisation
Stem-cell-derived hepatocyte Cyp3A function and stem-cell-derived hepatocyte




TTR secretion was determined as previously described (Hay et al., 2008).
HNF4a and albumin immunostaining were performed as previously described
(Medine et al., 2012).
Solexa
RNA was isolated from differentiating hESCs at days 0, 3, 10 and 17. Fetal and
adult hepatocyte RNA was also used. The cDNA obtained from the purified RNA
was initially cleaved to a uniform length between 200 and 500 bases and then
tagged using unique adapters and sequenced. The data was then analysed and
normalised to allow comparison of gene expression between the samples. Two
types for normalisation were used. First, the raw count of reads for each gene was
divided by the total number of reads aligned and multiplied by one million, thus
accounting for the depth of sequencing. Second, the results were divided by the
length of the gene multiplied by one thousand to obtain a read per kilo bases per
million reads value (RPKM) value.
Cellular protein extraction
Cells grown in a six-well plate were lysed in 150 ml of SUMO lysis buffer [2%
SDS, 50 mM Tris-HCl, pH 8, 1 mM ethylenediaminetetraacetic acid (EDTA) and
10 mM iodoacetamide (all from Sigma-Aldrich)] for 5 minutes at room
temperature. The cell extracts were sonicated and stored at 280 C˚ for later use.
Western blotting
Protein concentrations were measured using the standard BCA assay (Pierce).
40 mg of protein was then used for western blotting. The Nu-Page SURE Lock
system from Invitrogen was employed as per the manufacturer’s instructions. The
membranes were blocked for 1 hour at room temperature with PBS-Tween
containing 10% non-fat milk. They were then probed with primary antibody at 4 C˚
overnight under constant rotation. The secondary antibody was then incubated for
1 hour at room temperature, and detected using enhanced chemiluminescence
(ECL, Pierce). Details of antibodies used and sources are provided in
supplementary material Table S1.
Crosslinking antibodies
HNF4a (Santa Cruz) was crosslinked to Protein G beads (Sigma) as previously
described (Harlow, 1999).
Immunoprecipitation
The cell extract was diluted in incubation buffer (50 mM Tris-HCl, pH 8, 150 mM
NaCl, 5 mM EDTA, 2 mM DTT and 1% NP40). The cell extract was incubated
with the 1.5 mg of the HNF4a antibody (Santa Cruz Biotechnology) and a rabbit
IgG (Santa Cruz Biotechnology) was used as a control, for 3 hours at 4 C˚. Protein
G beads (Sigma-Aldrich) were prepared in NP40 buffer (50 mM Tris-HCl, pH 8,
150 mM NaCl, 5 mM EDTA and 1% NP40, Sigma-Aldrich). 20 ml of beads were
added to each sample and incubated overnight at 4 C˚ under constant rotation. The
samples were spun down at 3500 r.p.m. for 2 minutes, washed three times with the
incubation buffer and eluted with 26Disruption Buffer at 100 C˚ for 2 minutes.
The samples were then centrifuged at 13,000 r.p.m. for 5 minutes and analysed by
western blot with antibodies against SUMO1 and SUMO2.
Protein expression and purification
HNF4a wild-type and an N-terminal deletion mutant were kindly provided to us
by Primorigen Inc. The C-terminal deletions and the point mutant versions of the
HNF4a were generated by amplifying the respective fragment using primer
specific PCR The fragments were cloned into the pET15b Vector (Novagen),
using specific BamHI and NdeI restriction sites. All mutants contained a His tag
to confirm the expression and aid in the purification process. The constructs
were then transformed into BL21 E. coli (Stratagene) and selected clones were
grown at 37 C˚ until they reached an optical density of 0.5. At this point the
cultures were induced with 0.5 mM IPTG (Invitrogen) for 1 hour. After
induction the cells were spun down, lysed and purified as previously described
(Hoffmann and Roeder, 1991). Point Mutagenesis was carried out as directed by
the QuikChange II manual (Stratagene), the protein was expressed and purified
as described above.
In vitro SUMOylation assay
3 mg of each HNF4a variant was conjugated with the SUMO1 and SUMO2
proteins as previously described (Tatham et al., 2008). The SUMO deconjugation
was carried out as previously described (Shen et al., 2009).


















In vitro ubiquitination assay
1 mg of HNF4a was either mono or polySUMOylated as described above. The
ubiquitination machinery (8 mM of ubiquitin, 40 nM Uba1, 0.7 mM UbcH5a,
0.5 mM RNF4) was added to the reaction to make a total volume of 50 ml under the
following conditions: 50 mM Tris-HCl, 200 mM NaCl, 5 mM MgCl2, 1 mM
DTT, 2 mM ATP and 0.1% NP40. The reaction was incubated at 37 C˚ for 3–
4 hours. The HNF4a was immunoprecipitated out of the reaction using the
crosslinked beads specific to HNF4a and the eluate was analysed using western
blotting.
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